Atlas Trials

Clinical Study on Using TCR to Predict the Effect of Tislelizumab + Chemotherapy in the First-line Treatment of ES-SCLC

Clinical trial NCT07244016 · RECRUITING

Trial details

NCT number
NCT07244016
Sponsor
Henan Cancer Hospital
Status
RECRUITING
Study type
OBSERVATIONAL
Extensive-stage Small-cell Lung Cancer
Start date
2025-02-20
Primary completion
2026-12-30
Enrollment
40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.